BioCentury
ARTICLE | Clinical News

Mitobridge's DMD candidate MA-0211 enters Phase I

August 16, 2017 8:06 PM UTC

Mitobridge Inc. (Cambridge, Mass.) said that partner Astellas Pharma Inc. (Tokyo:4503) began a U.S. Phase I trial to evaluate once-daily oral doses of Duchenne muscular dystrophy (DMD) candidate MA-0211 (MTB-1) in healthy volunteers. The primary endpoints are safety and pharmacokinetics.

MA-0211 is an oral small molecule PPAR delta modulator. Mitobridge expects to begin a trial in ambulatory DMD patients next year...